Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a performance score (a measure of general health and ability to carry out daily activities) of 70 or above on the Karnofsky Performance Scale, indicating they are reasonably functional
- People who have between 1 and 4 tumours that have spread to the liver, where each tumour is no larger than 5 cm across
- People whose liver tumours cannot be removed by surgery, or who are considered not well enough to undergo surgery
- People whose original (primary) cancer was one of the following types: colorectal cancer (bowel cancer), cancer of the anal canal, or a gastrointestinal neuroendocrine tumour
- People who show no signs of cancer having spread outside the liver, or where any cancer outside the liver is being treated with the aim of curing it
- People who have had at least a 2-week gap between their last chemotherapy treatment and the start of radiation therapy
- People whose blood test results meet the following levels: a white blood cell count above 1,800 cells/mm³, a platelet count above 100,000 cells/mm³, and a haemoglobin level above 8.0 g/dL (including if reached through a blood transfusion or other support)
Who may not be able to join:
- People who are currently receiving chemotherapy at the same time as the trial treatment
- People who have previously had radiation therapy to the upper abdomen area
- People who are pregnant
- People who have cirrhosis (scarring of the liver)
- People who have active hepatitis or significant liver failure
- People who have had another cancer in the past, unless it was a non-melanoma skin cancer, or unless they have been free of that cancer for more than five years
- People with serious other health conditions (confirm with trial site for specific details)
- People who are currently taking blood-thinning (anticoagulant) medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andre TC Chen, MD, PhD, Instituto do Cancer do Estado de Sao Paulo
Phone: 55-11- 3893-4540
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Local Progression Free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.